Solid Tumor – NCI-09-C-0168
Dr. Elise C. Kohn
Principal Investigator
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial for patients with solid tumors. Click on the trial below for additional details, including a summary of primary eligibility, study outline, and information on how to contact Dr. Kohn and her staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
This is a Phase I, open-label study in subjects with solid tumors relapsed or refractory to standard therapy.
Dose escalation cohort:
- MEDI-547 will be administered according to two schedules: q3Week or qWeek
- Initially, subjects will enroll into the q3Week administration schedule at NIH
- Cohorts will enroll into the qWeek schedule at MD Anderson once the dose level in the q3Wk safely reaches 3 x the starting dose, in order to achieve equivalent cumulative dose per cycle
Dose expansion cohort:
- Patients with relapsed or refractory ovarian, fallopian tube, or primary peritoneal cancer whose tumor samples demonstrate EphA2 expression
Why is this trial important?
Many types of cancer cells express the EphA2 protein on the outside of their cells. People with EphA2-expressing cancers may have more aggressive types of cancer than people with cancer that does not express EphA2. The main purpose of this study is to determine the dose of MEDI-547 that is safe and tolerable when given to subjects. This study will also measure how much MEDI-547 is in your blood and whether the immune cells in your body have a reaction to MEDI-547. This study will also find out whether there are any changes in your cancer that could mean MEDI-547 has an effect on cancer cells.
Back to Top
